MedTrace Logo

An Investigation of Dexamethasone With Different Doses in the Management of Immune Thrombocytopenia (ITP)

NCT02153060 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 58

Last updated 2016-04-20

No results posted yet for this study

Summary

The project was undertaking by Qilu Hospital of Shandong University and other 7 well-known hospitals in China. In order to report the efficacy and safety of different dose dexamethasone in treating the immune thrombocytopenia (ITP).

Conditions

Interventions

DRUG

Dexamethasone

Dexamethasone was given at a dose of 40 mg,daily for 4 consecutive days

DRUG

Dexamethasone

Dexamethasone was given at a dose of 20 mg,daily for 4 consecutive days

Sponsors & Collaborators

  • Chinese Academy of Medical Sciences

    collaborator OTHER

  • Shandong Provincial Hospital

    collaborator OTHER_GOV

  • The First Affiliated Hospital of Dalian Medical University

    collaborator OTHER

  • Peking Union Medical College Hospital

    collaborator OTHER

  • Shandong University of Traditional Chinese Medicine

    collaborator OTHER

  • Anhui Provincial Hospital

    collaborator OTHER_GOV

  • Second Hospital of Shanxi Medical University

    collaborator OTHER

  • Shandong University

    lead OTHER

Principal Investigators

  • Ming Hou, DR. · Shandong University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
75 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2014-05-31
Primary Completion
2015-01-31
Completion
2015-08-31

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02153060 on ClinicalTrials.gov